Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03325491
Other study ID # 1617/024
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date March 7, 2018
Est. completion date September 16, 2019

Study information

Verified date September 2019
Source University of Exeter
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

As people grow older skeletal muscle gradually becomes smaller and weaker, causing reduced mobility and quality of life. To understand and reverse this negative process investigators need to find new ways of improving the ability of muscle to perform physical activity. There is some evidence that supplements may improve how the mitochondria work, and investigators want to explore this idea in more detail. This is possible by measuring how the muscles work and respond to exercise before and after taking the supplement alongside an aerobic (i.e. cycling) and resistance (i.e. weight lifting) exercise programme. This will give us the basic information investigators would need to see if this is a useful idea.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date September 16, 2019
Est. primary completion date September 16, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 65 Years to 75 Years
Eligibility Inclusion Criteria:

- Male

- Age between 65-75 years

- Body mass index between 19-29

- No active cardiovascular or metabolic disease

- No active respiratory disease

- No current musculoskeletal injuries

- A sedentary lifestyle (i.e. does not engage in strenuous, planned physical activity)

- The ability to give informed consent

Exclusion Criteria:

- Currently taking a statin drug or NSAIDs

- Have a current peptic ulcer

- Have any renal impairment

- Have a known hypersensitivity to Acipimox

- Suffer from vertigo

- Smoker

Study Design


Related Conditions & MeSH terms

  • Impaired Mitochondrial Function, Muscle Performance

Intervention

Dietary Supplement:
Acipimox
Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
Placebo
Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.

Locations

Country Name City State
United Kingdom NIHR Exeter Clinical Research Facility Exeter Devon

Sponsors (2)

Lead Sponsor Collaborator
University of Exeter Royal Devon and Exeter NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in mitochondrial function Mitochondria will be extracted from muscle samples immediately post-biopsy (biopsies taken baseline, week 3 and week 6) and analysed for content and subsequently for oxidative respiratory function using the Oroboros technique, and maximal rates of Adenosine Triphosphate (ATP) production. Baseline, 3 weeks, 6 weeks
Secondary Chronic changes in habitual muscle protein synthetic rates Baseline saliva samples then frequent saliva samples over 6 weeks following oral ingestion of the stable isotope deuterium oxide (D2O, or 'heavy water') will be analysed by gas-chromatography-pyrolysis-isotope ratio mass-spectrometry. analysis. Muscle samples collected at baseline, 3 weeks, 6 weeks will also be analysed by gas-chromatography-pyrolysis-isotope ratio mass-spectrometry Baseline, 3 weeks and 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT02792621 - Increasing Mitochondrial Function on Skeletal Muscle Performance in Older Men N/A